Compare Fabrinet (FN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Recursion Pharmaceuticals Inc — how do they compare? Fabrinet trades at $493.22 (market cap $17.46B), while Recursion Pharmaceuticals Inc trades at $4.28 (market cap $2.14B). The key difference: Fabrinet is far larger — about 8.2× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 1,199,886). Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FN | RXRX | |
|---|---|---|
Market Cap | $17.46B | $2.14B |
Volume | 1,199,886 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $746.47 | $6.79 |
52-Week Low | $361.94 | $2.84 |
Typical Hold Time | 30 Days | 22 Days |
Enterprise Value | $16.59B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $486.8, down 2.25% on the day, amid a mixed technical picture with a bullish moving average signal but overbought RSI levels. Fundamentally, the company shows strong growth with Q2 2026 EPS of $4.10 beating expectations, revenue projected to rise to $4.6B in 2026, and robust profitability metrics including a 21.33% ROE. Recent news highlights surging AI data center demand driving expansion.
The outlook is positive given analyst consensus of a $769.50 price target and 75% buy ratings, though risks include customer concentration and high capital expenditures impacting cash flow. The stock offers exposure to AI infrastructure growth but requires monitoring of execution and competitive pressures.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
